Rate and predictors of finding Monoclonal Gammopathy of Renal Significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy

Nattawat Klomjit, Nelson Leung, Fernando Fervenza, Sanjeev Sethi, Ladan Zand

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background Little is known about the rate and predictors of finding lesions of monoclonal gammopathy (MG) of renal significance (MGRS) on kidney biopsy specimens among patients with MG. Methods We reviewed the medical records from 2013 to 2018 at the Mayo Clinic in Rochester, Minnesota, to identify patients with MG and whether they had undergone a kidney biopsy. In a more select group of patients with MG from 2017 to 2018, we conducted a review of records to determine how many had underlying CKD, which of those with CKD had undergone a kidney biopsy, and reasons for deferring a kidney biopsy. Results Between 2013 and 2018, we identified 6300 patients who had MG, 160 (2.5%) of whom had undergone a kidney biopsy. Of the 160 patients, 64 (40%) had an MGRS lesion; amyloid light chain amyloidosis, the most common finding, accounted for nearly half of these lesions. In the non-MGRS group comprising 96 patients, 23 had arteriosclerosis, the most common finding. In multivariate analysis, strong predictors of finding an MGRS lesion included the presence of an elevated free light chain ratio, proteinuria, and hematuria. Among 596 patients with CKD and MG from 2017 to 2018, 62 (10.4%) underwent a kidney biopsy. Kidney biopsy was deferred for 70 patients (20%); for 62 of the 70, the diagnosis was already known, and eight were not candidates for therapy. Younger age and higher proteinuria and serum creatinine levels increased the likelihood that the patient would undergo a kidney biopsy. Conclusions Proteinuria $1.5 g/d, hematuria, and an elevated free light chain ratio increase the likelihood of finding MGRS, and a kidney biopsy should be highly considered in such patients.

Original languageEnglish (US)
Pages (from-to)2400-2411
Number of pages12
JournalJournal of the American Society of Nephrology
Volume31
Issue number10
DOIs
StatePublished - Oct 2020
Externally publishedYes

Bibliographical note

Funding Information:
N. Leung reports grants from Omeros, outside the submitted work. N. Leung is on an advisory board for AbbVie and Takeda. All remaining authors have nothing to disclose.

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Rate and predictors of finding Monoclonal Gammopathy of Renal Significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy'. Together they form a unique fingerprint.

Cite this